Y-mAbs Therapeutics (YMAB) Given “Buy” Rating at Cowen
Cowen reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note released on Tuesday, The Fly reports.
Separately, BTIG Research began coverage on Y-mAbs Therapeutics in a research report on Tuesday. They issued a buy rating and a $35.00 price target for the company.
NASDAQ:YMAB opened at $22.00 on Tuesday. Y-mAbs Therapeutics has a 1-year low of $18.00 and a 1-year high of $31.00.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
See Also: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.